The success of allogeneic stem cell transplantation and solidorgan transplantation owes much to improvements in the immunosuppressive regimens that prevent graft-versus-host disease (GVHD) or suppress allograft rejection. A better understanding of the immune mechanisms underlying induction of immunological tolerance is the key to successful transplantation. Polyclonal antibodies such as antithymocyte globulins (ATG) have been used for decades. The common belief is that ATG efficacy relies on its capacity to deplete T lymphocytes. The aim of this review is to offer an overview of the recent findings that have been demonstrated in ATG's immunomodulatory activity. The polyclonal nature of ATG is reflected in its diverse effects on the immune system: (1) T-cell depletion in blood and peripheral lymphoid tissues through complementdependent lysis and T-cell activation and apoptosis; (2) modulation of key cell surface molecules that mediate leukocyte/endothelium interactions; (3) induction of apoptosis in Bcell lineages; (4) interference with dendritic cell functional properties; and (5) induction of regulatory T and natural killer T cells. As a consequence, ATG provides multifaceted immunomodulation paving the way for future applications and suggesting that the use of ATG should be included in the immunosuppression therapeutic armamentarium to help reduce the incidence of organ rejection and GVHD.
Introduction
The success of allogeneic stem cell transplantation (allo-SCT) and solid-organ transplantation (SOT) owes much to improvements in the immunosuppressive regimens that prevent graftversus-host disease (GVHD) and/or suppress allograft rejection. For the past 20 years, the mainstay of immunosuppression has been the calcineurin antagonists cyclosporine A (CSA) and tacrolimus. However, their immunosuppressive effects can be unpredictable. Thus, a better understanding of the mechanisms of immunological tolerance to alloantigens, and development of new immunosuppressive strategies are the keys to successful allograft function. The so-called 'T-cell-depleting' antibodies such as antilymphocyte or antithymocyte globulins (ATG) have been used for decades. The general common belief is that ATG efficacy relies on its potent capacity to deplete T lymphocytes of the graft (as in allo-SCT) or of the host (as in SOT). ATG is used for treatment of various clinical conditions, including the prevention or rescue treatment of acute rejection in SOT, conditioning for allo-SCT, GVHD, treatment of severe aplastic anemia and various autoimmune diseases. An ever-growing body of recent data suggested that ATG affect not only T lymphocytes, but also other key cells involved in the immune reaction. Indeed, the immunosuppressive activity of ATG has been thought to result primarily from the depletion of peripheral T lymphocytes from the circulating pool through complementdependent lysis or activation-associated apoptosis. 1, 2 Other potential mechanisms of action include modulation of surface adhesion molecules or chemokine receptor expression. 3 In addition to their T-cell-depleting properties, ATGs can modulate the immune response by affecting or interfering with the function of different immune effectors such as B lymphocytes, regulatory T lymphocytes (Treg), natural killer (NK)-T lymphocytes and dendritic cells (DC). The aim of this review is to synthesize the recent biological effects that have been involved in ATGs immunomodulatory activity, and to suggest prospective future applications.
Generation of ATG, current available preparations, antibody specificities and pharmacokinetics
Polyclonal ATG is the purified IgG fraction of sera from rabbits, horses or, more rarely, goats that are immunized with thymocytes or T-cell lines. The most widely used preparations include horse ATG (Lymphoglobulin, Genzyme) and rabbit ATG (Thymoglobulin, Genzyme). ATG Fresenius (Fresenius-Biotech-GMBH, Gräfelfing, Germany) includes only rabbit antibodies, and is produced against the Jurkat cell line, which resembles activated T cells. ATG Pharmacia (Atgam, Pharmacia Upjohn) is derived from the horses immunized with thymocytes. Despite sharing some common properties, these different products are strictly different drugs, and have never been compared thus far in a controlled setting. Thus, one should be very cautious when deriving conclusions from the medical literature using these drugs. The rabbit preparation Thymoglobulin is probably the most extensively studied polyclonal antibody ATG preparation, and most of the available in vitro mechanistic data are derived from experiments performed using Thymoglobulin. Therefore, many data described in this review are from experiments performed with this product.
Thymoglobulin is produced by immunizing pathogen-free New Zealand rabbits with fresh human thymocytes. Thymus fragments are removed from donors undergoing cardiac surgery. Virologic screens are run on every thymus fragment prior to their use in the manufacturing process. The viral safety of this starting material is comparable to that of human blood derivatives used in transfusions. In addition, Thymoglobulin is a pasteurized product.
The immune cell types present in the normal human thymus, which serves as the source of thymocytes used to inoculate rabbits in the production of Thymoglobulin, have been extensively investigated. The distribution of cell types in the thymus includes T lymphocytes (72%), B lymphocytes (6%), and antigen-presenting cells (APC) and stromal cells (22%). 4 Table 1  summarizes the multitude of antibody specificities detected in  Thymoglobulin. 2,5-13 An ever-expanding array of target antigens is being characterized in Thymoglobulin. These antigens can broadly be categorized as immune response antigens, adhesion and cell-trafficking molecules and molecules involved in heterogeneous pathways. Antigens that have been shown to be involved in immune responses are found on T cells, B cells, NK cells, macrophages and DCs. Adhesion and cell-trafficking antigens are also found abundantly. Other antigens involved in heterogeneous pathways (inflammation, apoptosis, proliferation,yetc) have also been characterized (Table 1) . 2, 4, 7, 8, [10] [11] [12] [13] [14] [15] ATG pharmacokinetics depends on the dose and schedule of administration as well as the number of 'targeted' immune effectors. The pharmacokinetics of ATG was studied initially in the SOT setting, and clearance of ATG was found to be consistent with single exponential decay and elimination halflife of 30 days demonstrating that rabbit ATG has a long half-life in human plasma and an apparent volume of distribution of about twice plasma volume. 16 Studies of the clearance of ATG given as part of the preparative regimen prior to allo-SCT indicated that the levels of rabbit ATG gradually declined, but could still be detected up to 5 weeks after allo-SCT. 17 Interestingly, the latter study found a correlation between the grade of acute GVHD and the concentration of ATG in serum before transplantation. Patients with high serum levels of ATG before allo-SCT had a low risk of developing severe acute GVHD, as compared to those with lower levels, suggesting that the measurement of ATG levels may be of value. 17 However, these studies and most studies of ATG pharmacokinetics have measured ATG in blood samples using an ELISA assay that may overestimate the levels of biologically active antibody molecules. Waller et al. addressed this issue and could show that in all, the type of ATG, the timing of ATG administration during the conditioning regimen and the total dose of ATG appear to be important factors on the overall clinical impact. However, persistence of significant long-term deficits in T-cell reconstitution was linked to impaired thymopoiesis rather than to persistent active ATG that declined to sub-therapeutic levels by 1 month after allo-SCT. 18 
ATG and T-cell depletion
A well-documented effect of treatment with ATG is T-cell depletion. When looking at the composition of the ATG preparation (Table 1) , T-cell target antigens such as CD3/TCR and CD152 are T-lineage specific. Molecules such as CD2, CD4, CD5, CD6, CD8, CD25 and CD28 are expressed predominantly, although not exclusively, on T cells. HLA class I molecules can be found on all nucleated cells. CD2 is also present on NK cells, and CD4 can be found on monocytes, DCs and macrophages. CD5 is found on a subset of B cells, and the activation marker CD25 is also present on B cells and monocytes. Both CD28 and CD30 are also present on activated B cells. It is well established that low T-cell counts are usually achieved in peripheral blood after ATG treatment, but the extent of T-cell depletion in lymphoid tissues has been characterized in cynomolgus monkeys using Thymoglobulin at low, high and very high doses. Four protocols of administration of Thymoglobulin were studied. The low dose (equivalent to 0.15-0.20 mg/ kg/day in humans) is not used clinically; however, it resulted in serum concentrations equivalent to those observed in SOT. High dose (equivalent to 0.8-1.0 mg/kg/day in humans) corresponds to the clinical dosage used in SOT. Very high dose (equivalent to 3.5 mg/kg/day in humans) corresponds to that used clinically for allo-SCT. 10 In this animal model, there was a dose-dependent depletion of T cells as indicated by CD3 þ cell decrease. Moreover, both T-cell subsets, CD4 þ and CD8 þ cells, were also depleted in a dose-dependent manner. CD20 þ cells (B cells) and CD16 þ /56 þ cells (NK cells) were also found to decrease. However, it is important to bear in mind that circulating lymphocytes in the periphery at any given time represent only a small percentage of total lymphocytes. Thus, examining lymphocyte depletion in the secondary lymphoid organs would provide a more accurate picture of T-cell depletion. Indeed, depletion of T cells was observed in the spleen, and in the lymph nodes, where depletion of both CD4 þ and CD8 þ T cells was clearly dependent on the dose of Thymoglobulin. B cells and NK cells were affected only at the very high dose. These data extend the observation that Thymoglobulin provides T-cell depletion beyond peripheral lymphocytes to depletion within secondary lymphoid tissues of spleen and lymph nodes. The underlying mechanisms of T-cell depletion by ATG include complement-dependent lysis, predominantly in the blood compartment. Indeed, complementdependent lysis is likely to contribute to the depletion of T cells, especially in the intravascular compartment, where the concentration of complement proteins is maximal. Concentrations that are attained in the serum during treatment with ATG efficiently activate human complement in clinically relevant situations. 1, 19 In peripheral lymphoid tissues, apoptosis with subsequent phagocytosis by macrophages appears to be the primary mechanism. In the cynomolgus monkey model, T-cell depletion in the lymph nodes was associated with apoptosis. Apoptosis was documented by externalization of membrane phosphatidyl-serine measured by the binding of annexin V in FACS analysis. TUNEL analysis of sections of lymph nodes also revealed DNA breaks, indicative of apoptosis. With both Table 1 Summary of known target antigens for antithymocyte globulin
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methods, the percent of apoptotic cells was related to the dose of Thymoglobulin administered. 10 A third mechanism is opsonization by immunoglobulin antibodies and complement followed by phagocytosis of opsonized lymphocytes. Nevertheless, the latter mechanism is still hypothetical. 1, 10 With respect to activated T cells, depletion of pre-activated T cells with ATG may occur through two different pathways, the antibody-dependent cell-mediated cytotoxicity or Fas-dependent apoptosis. The concentrations of Thymoglobulin necessary to trigger either cytotoxic mechanism are lower (10 mg/ml) than those required to destroy resting T cells (100 mg/ml). 1, 20 Because of the high affinity of Thymoglobulin antibodies for the human Fc receptor, antibody-dependent cell-mediated cytotoxicity can be achieved at very low antibody density on the membrane of targeted T cells. This activity is independent of antibody specificity, and it occurs primarily with activated T cells as targets. Resting lymphocytes are less susceptible to this cytotoxic pathway. 1 The translation of these findings into clinical treatment regimens requires some caution. The central mechanisms of depletion (i.e. complement-dependent lysis and activation-associated apoptosis) are dose-dependent and are not influenced by corticosteroids, CSA or rapamycin. T-cell depletion in both the intravascular and lymphoid compartment requires supramitogenic concentrations of Thymoglobulin that can be achieved with a dose of 2-3 mg/kg for 2-4 days. This is the reason why low-dose regimens are probably not sufficient for a substantial depletion in the secondary lymphoid organs but will achieve blood levels high enough for antibody-dependent cell cytotoxicity (0.1-1 mg/ml) and activation-induced cell death (10-100 mg/ml).
Modulation of adhesion and cell-trafficking molecules by ATG
Adhesion molecules and leukocyte infiltration play a key role in SOT (i.e. ischemia-reperfusion injury), GVHD and rejection. [21] [22] [23] [24] Lymphocyte/endothelium interactions are a complex series of events initiated by lymphocytes sticking then rolling along the surface of the endothelium. Inflammatory mediators such as cytokines are released and the endothelium changes from an anti-adhesive to a pro-adhesive status. Selectins and integrins on the surfaces of lymphocytes and the endothelium play a critical role in this process. These events are important in the initiation of allograft rejection and ischemia reperfusion injury. After engagement, an activation step occurs next with fixation of b-chemokines on endothelial cells through CXCR4, CCR5 and CCR7. Leukocyte integrin b-4-beta-7 (LPAM-1), LFA-1 and VLA-4 are activated. Leukocyte arrest is achieved through the interactions of integrins and immunoglobulin superfamily adhesion receptors. Thymoglobulin contains antibodies specific for the integrins LPAM-1 and VLA-4, the chemokine receptors CXCR4, CCR5 and CCR7, and the leukocyte adhesion receptors ICAM-1, -2 and -3 (Table 1) . 2, 25 In general, modulation (i.e. the internalization of the antigen-antibody complexes after binding) is a major functional mechanism of action of ATG. When the surface antigen is no longer expressed, the related pathway is inhibited as long as the antibody is present. Such downregulation of surface antigens is not restricted to the blood compartment but occurs in secondary lymphoid organs as well.
10 Down-modulation is not inhibited by corticosteroids, calcineurin inhibitors or rapamycin. 2, 10, 26 Such antibodyinduced modulation modifies the interactions between leukocytes and endothelium. Some of the target antigens in Thymoglobulin, involved in the modulation of cell surface adhesion proteins and chemokine receptors, are of great importance. LFA-1, the leukocyte function-associated antigen, is an intercellular adhesion molecule selectively expressed on leukocytes. The three ligands of LFA-1 are the leukocyte adhesion receptors ICAM-1, ICAM-2 and ICAM-3. LPAM-1 and VLA-4 are integrins, a large family of glycoproteins that attach cells to ligands on other cells. LPAM-1 is the ligand for MAdCAM-1, and VLA-4 is the ligand for VCAM-1. CXCR4, CCR7 and CCR7 are chemokine receptors important for leukocyte/endothelium interactions and leukocyte trafficking. 2, 3, 7, 8, 10, 12 Surface expression of LFA-1 has been determined at various times in the presence of increasing concentrations of Thymoglobulin. The results show a down-modulation of LFA-1 on lymphocytes, monocytes and neutrophils. This downmodulation occurs even at low drug concentrations. However, there is a clear dose response to increasing drug concentrations. The down-modulation of LFA-1 makes it no longer available for cellcell interactions, such as those in leukocyte/endothelium interactions. Thymoglobulin also contains antibodies to ICAM-1 (CD54), the main ligand of LFA-1, ICAM-2 (CD102) and ICAM-3 (CD50). The ability to down-modulate LFA-1 occurs at drug concentrations that are substantially below concentrations achieved in clinical use (80-200 mg/ml).
1,2,19 A similar downmodulation of CD49d, the b chain of the leukocyte integrin VLA-4, is observed on lymphocytes and monocytes when incubated with increasing drug concentrations. The leukocyte integrin b-4-beta-7 (LPAM-1) has also been shown to be downmodulated. Thymoglobulin also contains antibodies to CD49e and CD49f (VLA-5 and VLA-6). 2 With respect to chemokine receptors, human lymphocytes or phytohemagglutinin-activated blasts mixed in vitro with Thymoglobulin shows moderate, but significant down-modulation of cell-surface expression of CCR7. 2 In addition to downmodulation of the CCR7 chemokine receptor, the presence of antibodies to CXCR4 and CCR5 was shown by the decreased binding of specific monoclonal antibodies to lymphocytes and monocytes. 2 The range of adhesion molecules and chemokine receptors down-modulated may contribute to the therapeutic effect of ATG. The latter was demonstrated in a primate model of ischemia-reperfusion. In this model, ABO-compatible human blood was pre-incubated with saline, and a CD25 monoclonal antibody or Thymoglobulin. The treated blood was infused into the femoral artery of a cynomolgus monkey after 1 h of warm ischemia. The microcirculation was observed through an intravital microscope and CDD camera. The results demonstrated rolling and massive sticking of leukocytes with control blood treated with saline or with a CD25 monoclonal antibody. By comparison, there was no clumping or agglutination with blood treated with Thymoglobulin. 27 While it is now clearly established that ATG induces the modulation of key functional molecules that mediate leukocyte/ endothelium interactions, and interferes with leukocyte adhesion to the endothelium in vivo, some crucial factors should be taken into consideration in optimizing clinical application of these findings. Timing of drug administration appears to be a key factor in both the SOT 3,28-30 and allo-SCT settings, 31 but further studies are still needed to evaluate the differential impact of ATG on the increasing number of adhesion molecules and their tissue location, recycling patterns and role in different clinical settings.
Effects of ATG on B lymphocytes
B cells are precursors to plasma cells, which are involved in humoral rejection. Interestingly, it has been reported previously that polyclonal rabbit ATG can be used with plasmapheresis to treat antibody-mediated renal allograft rejection. 32 ATG preparations, especially Thymoglobulin, have been shown to contain antibodies against a number of B-cell antigens, including B-cell-specific and non-specific surface proteins CD19, CD20, CD40, CD80, CD30, CD38 and CD95. Antibodies against the plasma cell-specific marker CD138 were also characterized. 4, 7, 8, 11, 12, 14 With this background, Zand et al. tested the complement-independent, apoptosis-inducing properties of Thymoglobulin on naïve B cells, CD40 ligand-activated B cells and plasma cells. Potential surface targets were assayed by competitive inhibition of monoclonal antibody binding. Thymoglobulin was found strongly to induce apoptosis in vitro against naive, activated B cells and bone marrow resident plasma cells at clinically relevant concentrations (1-100 ng/ml). Such activity was described against numerous B-cell surface proteins and the authors observed that cross-linking of CD30, CD38, CD95, CD80 and HLA-DR likely accounts for this activity. F(ab')2 fragments of rATG showed 90% of the activity of the intact molecule, suggesting participation of the Fc fragment. Inhibition of caspase-and cathepsin-dependent apoptotic pathways partially inhibits Thymoglobulin-induced B-cell apoptosis. 4 The impact of ATG on normal B cells was extended to myeloma cells. Both ATG-Fresenius 33 demonstrated potent anti-myeloma activity of Thymoglobulin in vitro and in vivo in an animal model of myeloma. Thymoglobulin was able to induce dose-and time-dependent apoptosis of several myeloma cell lines, including those resistant to conventional anti-myeloma agents. Importantly, the anti-myeloma activity was preserved even when myeloma cells were grown with different cytokines demonstrating the ability to overcome microenvironment-mediated resistance. Thymoglobulin induced the apoptosis of freshly isolated primary myeloma cells from patients, and in a plasmacytoma mouse model of myeloma, Thymoglobulin delayed the tumor growth in a dosedependent manner providing evidence for prospective evaluation of ATG in patients with myeloma, either alone or in combination with other agents.
Effects of ATG on DCs
Being the most potent APCs both in vitro and in vivo, DCs play a key role in the initiation of the immune response and are considered promising targets for immunotherapy. In the transplantation field, both donor and recipient DCs play a major role, and depending on the environment in which the immune interactions between DCs and effector T cells take place, an inflammatory or a tolerogenic effect can occur. DCs can be activated by inflammatory cytokines, or microbial products such as lipopolysaccharide (LPS) and toll-like receptor (TLR) ligands. These effects are extremely important in producing the 'danger signals' that mature DCs and lead to T-cell activation, whereas immature DCs induce T-cell tolerance. A working paradigm for DC function holds on the fact that immature DCs are distributed in peripheral tissues, and that they are specialized for uptake of pathogen-derived antigens. 35, 36 Pathogen-derived products can activate DCs via TLRs to migrate to secondary lymphoid organs and to present antigens rather than antigen uptake. 37 Mature DCs have increased expression of MHC and costimulatory molecules, and cytokines that promote adaptive immunity.
In transplantation, DCs are likely to determine the balance between rejection and tolerance. In SOT, implantation of the graft represents the 'danger' signal activating the immune system. One response that takes place is the release of chemokines and cytokines from immature donor DCs within the graft as well as the maturation of these DCs. These mature donor DCs enter the circulation via high endothelial venules and traffic to lymph nodes where they encounter recipient T cells (Figure 1) . The interactions between activated DCs and T cells would trigger rejection or tolerance. The maturation status of DCs has also been proposed to play a role in the induction and maintenance of peripheral tolerance, with immature DCs being considered as 'tolerogenic'. 38 Thus, one can imagine donor immune effectors entering secondary lymphoid tissues in which they will encounter a mix of mature and immature DCs, but also different DC subsets. In humans, at least two subsets of peripheral blood circulating DCs have been characterized thus far: the myeloid (MDC) and plasmacytoid (PDC) subsets. MDCs demonstrate remarkable plasticity and, ). The role of DCs is now well demonstrated as a factor of major importance in the hierarchy of the induction of immune reactions. Therefore, GVHD or solid-organ-graft rejection pathophysiology is likely to involve complex interactions where DCs and effectors from both the adaptive and innate immune system play a major role before the establishment of the allogeneic immune response.
With this background, the impact of ATG has been investigated on the phenotype and function of DCs generated in vitro. First, Monti et al. attempted to determine whether ATG is able to bind and interfere with human DC function. ATG bound to human DCs at least in part by recognizing CD1a, MHC I, MHC II, CD11a, CD86, CD32, CD4, CD11b, CD29 and CD51/61. This binding, which was more relevant in mature DCs, induced complement-mediated lysis. ATG did not influence either the macropynocytosis properties of DCs or the receptor-mediated endocytosis of FITC-Dextran. In MLR assay, ATG was able to significantly inhibit T-cell proliferation by binding on T cell but not on DCs, suggesting that ATG is able to interfere in the activation of T cells by DCs in two different ways: by inhibiting the capacity of lymphocyte to proliferate after the DC stimulation and by inducing a complement-mediated lysis of DC. 12 More recently, Gillet-Hladky et al. 40 investigated ATG effects on in vitro differentiation and maturation of monocyte-derived DCs (Mo-DCs). ATG was found to inhibit the maturation of immature Mo-DCs and allowed the generation of DCs expressing ILT-3, CD123, CCR6 but not CCR7 and producing indoleamine 2,3-dioxygenase mRNA, a phenotype compatible with tolerogenic DCs. In the allo-SCT setting, Fang et al. found that after incubation of peripheral blood mononuclear cells from healthy donors with ATG-Fresenius and complement, there was a significant reduction of both MDCs and PDCs. The mean relative reduction of PDC and MDC numbers after ATG and complement treatment was approximately 80 and 85%, respectively. The authors further confirmed these findings in vivo in blood samples from patients treated with or without ATG, collected immediately after completing cytotoxic therapy or after ATG treatment. Despite a marked decrease of circulating MDCs and PDCs after both ATG and cytotoxic therapy, complete depletion of both types of DCs was observed in patients only after the ATGcontaining conditioning. 41 However, the actual impact of ATG on tissue DCs such as Langerhans' cells or dermal intestinal DCs is still unknown. The latter might be of great clinical relevance, because these DC subsets are located in the organs mainly affected by GVHD. However, the above results support the hypothesis that reduction of GVHD or solid-organ-graft rejection after ATG pretreatment may be caused not only by the substantial in vivo T-cell depletion, but also by a significant effect on DCs that are likely oriented towards a tolerogenic phenotype.
Effects of ATG on regulatory and NK-T cells
Dominant tolerance is now known to be assured by multiple subtypes of regulatory and suppressor T lymphocytes. 42 The 50, 51 An ever-growing body of evidence supports important immunoregulatory functions of Treg in maintaining both self-tolerance and tolerance toward autoantigens 52 and alloantigens. 53 Thus, efforts are currently ongoing to optimize in vitro methods for Treg generation, 54, 55 and clinical trials were already proposed to use ex vivo expanded Treg. 56, 57 Therefore, understanding the conditions that are required for the generation of Treg would allow the development of novel strategies for inducing immunologic tolerance. With this background, Lopez et al. 58 assayed the ability of Thymoglobulin to impact the generation of Treg in vitro. They reported for the first time that Thymoglobulin, but not the anti-CD52 mAb (alemtuzumab) or the IL-2R antagonists causes rapid and sustained expansion of CD4 þ CD25 þ T cells when cultured with human peripheral blood lymphocytes. The expanded cells displayed enhanced expression of GITR, CTLA-4, Foxp3 and efficiently suppressed a direct alloimmune response of the original responder lymphocytes. It is interesting to note that these cells did not suppress memory responses. Ex vivo expansion of Treg was due mainly to conversion of CD4 þ CD25-into CD4 þ CD25 þ T cells and to a lesser degree to proliferation of natural CD4 þ CD25 þ T cells. The induction of Treg depended on production of Th2 cytokines in the generating cultures. Although the in vivo effects of ATG on the induction, expansion and function of Treg in allograft recipients remain to be characterized fully, these novel data suggest that ATG not only may promote expansion/generation of Treg cells, but may also be useful in future ex vivo expansion of these cells for cellular therapy in autoimmunity and transplantation.
In comparison to the naturally occurring Treg lymphocytes, NK-T cells are a subset of T cells that recognize CD1d, a nonpolymorphic, class I, MHC-like antigen-presenting molecule. Recognition is mediated by the means of a T-cell receptor that includes an invariant TCR b-chain with rearranged Va14 and Ja281 gene segments in mice. NK-T cells are predominantly CD4À/CD8À, and secrete large amounts of IL-4 and IFNgamma after engagement of the CD3/TCR without previous exposure to antigens. 59 In a mouse model assessing the impact of antithymocyte serum (the mouse equivalent to rabbit ATG), Lan et al. showed that NK-T cells become predominant after total lymphoid irradiation (TLI) and rabbit antithymocyte serum (ATS) treatment of C57BL/6 spleen cells. Interestingly, although the overall population of TCRab decreased from 33.2 to 3.6%, NK-T cells represented 92.4% of these cells after completion of the regimen. 60 Host mice conditioned with TLI and ATS have improved survival compared with those having total-body irradiation (TBI) and ATS after allogeneic bone marrow transplantation (BMT). In addition, injection of ATS during the second week of TLI protected the hosts further such that the combined infusion of marrow and PBMC failed to kill any hosts during a 120-day observation period. 60 Most importantly, to determine whether protection against GVHD after TLI and ATS conditioning required the presence of host NK-T cells, the ability of bone marrow and PBMC mixtures from MHC mismatched donors to induce GVHD in either wild-type or NK-T-cell deficient CD1À/À hosts was determined. Differential survival of wild-type and NK-T-cell deficient CD1À/À hosts after BMT from MHC mismatched donors demonstrated the requirement for NK-T cells in the suppression of GVHD. 61 NK-T-cell suppression of GVHD required IL-4, 62 with the resultant Th2-polarized donor T cells as weaker inducers of GVHD compared with Th1-polarized donor T cells. 63 The finding that conditioning with TLI and ATS protects mice against acute GVHD after allo-SCT prompted the Stanford group to test this strategy in humans. Of 37 allo-SCT recipients, only two had acute GVHD after allo-SCT. In the transplant recipients, the fraction of donor CD4 þ T cells that produced IL-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a singlelow-dose TBI (200 cGy), strongly confirming the ability of a regimen of TLI and Thymoglobulin to decrease the incidence of acute GVHD, while allowing graft antitumor activity. 64 Similarly, in the SOT setting, Brennan et al. prospectively compared short courses of ATG (Thymoglobulin) and basiliximab in patients at high risk for acute rejection or delayed graft function who received a renal transplant from a deceased donor. At 12 months, the ATG group, as compared with the basiliximab group, had significantly lower incidences of acute rejection and of acute rejection that required treatment with antibody, suggesting that ATG-based induction therapy, as compared with basiliximab, reduced the incidence and severity of acute rejection in the renal SOT setting. 65 
Conclusions and future perspectives
The polyclonal nature of ATG is reflected in its diverse effects on the immune system: (1) T-cell depletion in blood and peripheral lymphoid tissues through complement-dependent lysis and T-cell activation and apoptosis; (2) modulation of key cellsurface molecules that mediate leukocyte/endothelium interactions; (3) induction of apoptosis in B-cell lineages and myeloma cell lines; (4) interference with DC functional properties; and (5) induction of Treg and NK-T cells. As a consequence, ATG provides multifaceted immunomodulation (Figure 1) , which is worth continuous investigation in different clinical settings. The current research evidence suggests prospective future applications for ATG based on the recently characterized immunomodulatory effects. Historically, however, ATG-based immunosuppressive therapy -both in SOT and allo-SCT -has gone in and out of favor. In the early era of SOT and allo-SCT, immunosuppressive options were limited to the use of corticosteroids, azathioprine and methotrexate. ATG was used clinically in the 1970s, but there was controversy over its efficacy, production and especially production standardization. The introduction of CSA in the early 1980s was a major advance. SOT and allo-SCT results were significantly improved and the enthusiasm for ATG in general declined. The advent of reducedintensity conditioning regimens in allo-SCT, the increasing use of organs with a high risk of delayed function in the SOT field, and the discovery of different new mechanisms of action for ATG with a better knowledge of dosages, safety and tolerance renewed the interest for the use of polyclonal antibodies. The SOT and allo-SCT communities are now faced with the challenge on how to define new immunosuppressive strategies, including ATG, which will optimize the outcome of transplantation. Prospective and randomized studies assessing ATG benefits are needed because a strong body of evidence suggests that the use of ATG as part of the immunosuppression therapeutic armamentarium may help reduce the incidence and severity of clinically significant cellular rejection in SOT and GVHD in allo-SCT.
